Pipeline
Screen
Diagnostics
Treatment
Monitoring
TNBC Exosomal Biomarker Panel
Breast cancer is the most frequent tumor worldwide approximately 10% to 20% of these patients will be diagnosed with a group of breast cancers defined by the lack of expression of and/or amplification of targetable biomarkers. Triple-negative breast cancers (TNBC) present with a varied natural history but are collectively associated with poor prognosis with high risk of relapse and short progression-free survival (PFS) and overall survival (OS). As many as 50% of patients diagnosed with early-stage TNBC experience disease recurrence, and 37% die in the first 5 years after surgery. Similarly, patients with metastatic triple-negative breast cancer have short PFS after failure of first-line chemotherapy, indicating the pressing need for drug development for treating TNBC. To date, current guidelines support that triple-negative breast cancer should be treated with conventional strategies primarily driven by the patient’s characteristics and the toxicity profile of the treatment to be chosen.
Exonox plans to further develop genomic quantitative assessment to characterize TNBC for the initiation of disease, response to treatment selections and potential of migration. Still, no assays for minimal invasive exam or test are available to guide the treatment in a clear direction. We have initiated a study to follow TNBC patients for differential level of biomarkers either on the exosomes or in the circulation from diagnosis to prognosis. We expects to discover a panel of biomarkers to assist oncologist to monitor TNBC patients’ disease progress with Exonox’s cutting edge tools and experties.
Currently, we have already built an exosomal biomarker (protein) panel from TNBC clinical samples. This biomarker panel has great potential to be directly used as a liquid biopsy to discriminate the TNBC and other groups (Luminal A, HER2+). In addition, the Exonox team has also discovered some exosomal protein biomarkers which are related to tumor development, such as tumor proliferation, migration, invasion, and metastasis. These protein biomarkers could also be associated with the druggable targets for TNBC exosome-based treatment. We are now doing the verification of these exosomal protein biomarkers via targeted mass-based proteomics.
Dual-Biomarker One-Step ELISA of Early Renal Injury (mAb, pAb) (Human)
Renal injury, also called nephropathy, can be caused by, for example, drug toxicity, inflammatory reactions, high blood pressure and diabetes. Kidney disease is usually a progressive disease, which means that kidney damage is often permanent and irreversible. It is very important to detect kidney disease as early as possible before permanent damage occurs.
Exonox is developing a dual-biomarker diagnostic tool – Exonox® Renal ELISA, that is able to detect urine and plasma samples with early renal injury despite patients’ concomitant diseases such as Type 2 Diabetes. By using Exonox® Renal ELISA, it could help doctors to monitor patients’ renal status at early stage and give suitable treatment or healthcare in time.
Dual-Biomarker Rapid Test of Early Renal Injury (Pet Cat)
Kidney disease is the first cause of death in pet cats, and the existing blood tests: creatinine (creatinine), blood urea nitrogen (BUN) have low sensitivity, and only remaining 30~40% of the cat’s kidney function is detected as kidney disease.
Exonox is developing a dual-biomarker diagnostic tool – Exonox®Renal Pet Cat Rapid Test, that is able to detect urine samples with non-invasive methods for early nephropathy in 30 minutes, which should provide veterinarians with detection evidence and early intervention in the renal function management of pet cats.